Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Mereo BioPharma Group plc American Depositary Shares

MREO

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Last trade $0.2692
Day change -$0.0358 (-11.74%)
Day range $0.265 – $0.303
Volume 880,258
Market cap $49M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for MREO.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for MREO.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Soleno Therapeutics, where investors who purchased stock between March 26, 2025 and November 4, 2025 may be entitled to compensation. The lawsuit alleges Soleno made false statements about safety concerns related to its DCCR drug candidate, including fluid retention issues in clinical trials, which posed greater risks than disclosed and reduced commercial viability. The lead plaintiff deadline is May 5, 2026.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO

Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.